APA (7th ed.) Citation

Chanan-Khan, A., Cramer, P., Demirkan, F., Fraser, G., Silva, R. S., Grosicki, S., . . . Mato, A. (2016). Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): A randomised, double-blind, phase 3 study. Lancet Oncology, 17(2), 200. https://doi.org/10.1016/S1470-2045(15)00465-9

Chicago Style (17th ed.) Citation

Chanan-Khan, Asher, et al. "Ibrutinib Combined with Bendamustine and Rituximab Compared with Placebo, Bendamustine, and Rituximab for Previously Treated Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma (HELIOS): A Randomised, Double-blind, Phase 3 Study." Lancet Oncology 17, no. 2 (2016): 200. https://doi.org/10.1016/S1470-2045(15)00465-9.

MLA (9th ed.) Citation

Chanan-Khan, Asher, et al. "Ibrutinib Combined with Bendamustine and Rituximab Compared with Placebo, Bendamustine, and Rituximab for Previously Treated Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma (HELIOS): A Randomised, Double-blind, Phase 3 Study." Lancet Oncology, vol. 17, no. 2, 2016, p. 200, https://doi.org/10.1016/S1470-2045(15)00465-9.